Phospho-BLK (Y501) Antibody

What is BLK protein and what is the significance of Y501 phosphorylation?

BLK (BLK proto-oncogene, Src family tyrosine kinase) is a nonreceptor tyrosine-kinase belonging to the Src family of proto-oncogenes that play crucial roles in cell proliferation and differentiation. The protein has significant functions in B-cell receptor signaling and B-cell development. Additionally, BLK stimulates insulin synthesis and secretion in response to glucose and enhances the expression of several pancreatic beta-cell transcription factors .

Y501 phosphorylation represents a key regulatory modification site on the BLK protein. When this site is phosphorylated, it serves as an inhibitory mechanism for BLK kinase activity. Conversely, mutations at this site (such as Y501F) create a constitutively active form of BLK that can transform cytokine-dependent cells into cytokine-independent ones, demonstrating its potential oncogenic properties .

What applications is the Phospho-BLK (Y501) Antibody validated for?

The Phospho-BLK (Y501) Antibody has been validated for multiple research applications:

• Enzyme-Linked Immunosorbent Assay (ELISA) - with recommended dilution of 1:20000

• Immunohistochemistry (IHC) - with recommended dilution range of 1:100-1:300

• Immunofluorescence (IF) - with recommended dilution range of 1:50-200

The antibody has been tested and confirmed to work effectively in these applications, making it suitable for various research protocols investigating BLK phosphorylation status .

What species reactivity does the Phospho-BLK (Y501) Antibody have?

The Phospho-BLK (Y501) Antibody has confirmed reactivity across three species:

• Human - recognizes phosphorylation at tyrosine 501 (Y501)

• Mouse - recognizes the equivalent phosphorylation at tyrosine 495 (Y495)

• Rat - recognizes the equivalent phosphorylation at tyrosine 495 (Y495)

This multi-species reactivity makes the antibody valuable for comparative studies across different model systems and translational research between animal models and human samples .

How should the Phospho-BLK (Y501) Antibody be stored for optimal performance?

For optimal antibody performance and longevity, adhere to these storage recommendations:

• Long-term storage: Store at -20°C for up to one year from the date of receipt

• Short-term storage: For frequent use, store at 4°C for up to one month

• Formulation: The antibody is typically provided in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide

• Handling precautions: Avoid repeated freeze-thaw cycles as this can degrade antibody quality and compromise experimental results

Following these storage guidelines will help maintain antibody specificity and sensitivity throughout your research timeline.

How can I validate the specificity of the Phospho-BLK (Y501) Antibody in my experimental system?

To confirm antibody specificity in your particular experimental system, consider implementing these validation approaches:

• Blocking peptide experiment: Incubate the antibody with the phospho-peptide immunogen before application. As demonstrated in immunohistochemistry analysis of paraffin-embedded human breast carcinoma, signal should be significantly reduced or eliminated when blocked with the phospho-peptide .

• Positive and negative controls:

  • Use samples known to express phosphorylated BLK at Y501

  • Employ phosphatase treatment to remove phosphorylation as a negative control

  • Compare with samples expressing the Y501F mutation (which cannot be phosphorylated at this site)

• Comparative analysis with total BLK antibody: Use an antibody that detects total BLK protein regardless of phosphorylation status to confirm the presence of the protein and compare signal patterns .

• Inhibitor experiments: Treat cells with Src family kinase inhibitors such as dasatinib or Lck inhibitor, which have been shown to inhibit BLK phosphorylation, and confirm signal reduction .

What are the optimal experimental conditions for using Phospho-BLK (Y501) Antibody in IHC applications?

For optimal IHC performance with the Phospho-BLK (Y501) Antibody:

• Sample preparation:

  • Use appropriate fixation (typically formalin-fixed, paraffin-embedded sections)

  • Perform antigen retrieval to expose the phospho-epitope (methods may vary depending on tissue type)

  • Include phosphatase inhibitors in buffers to preserve phosphorylation status

• Antibody concentration:

  • Begin with the recommended dilution range (1:100-1:300)

  • Conduct titration experiments to determine optimal concentration for your specific tissue

  • Consider longer incubation times (overnight at 4°C) for improved signal-to-noise ratio

• Detection system:

  • Use a high-sensitivity detection system appropriate for your tissue

  • Consider signal amplification methods for low-abundance targets

• Controls:

  • Include a blocking peptide control as demonstrated in the immunohistochemistry analysis of human breast carcinoma

  • Use tissues known to express or lack phosphorylated BLK as positive and negative controls

How does the phosphorylation status of Y501 relate to BLK's biological functions?

The phosphorylation status of Y501 serves as a critical regulatory switch for BLK's biological functions:

• Kinase regulation: Y501 phosphorylation is inhibitory to BLK kinase activity. When phosphorylated, BLK adopts a closed conformation with reduced catalytic activity .

• Oncogenic potential: The constitutively active form of BLK (Y501F), which cannot be phosphorylated at this site, transforms growth factor-dependent cells into factor-independent cells. This mutation promotes cell survival and proliferation in the absence of growth factors, demonstrating oncogenic potential .

• Signaling pathway modulation:

  • In B-cell receptor signaling, Y501 phosphorylation status affects downstream pathway activation

  • In pancreatic β-cells, BLK phosphorylation impacts insulin synthesis and secretion pathways

• Therapeutic implications: Src family kinase inhibitors like dasatinib and Lck inhibitor (LckI) can inhibit BLK activity and suppress proliferation of cells with active BLK, suggesting potential therapeutic applications in malignancies with aberrant BLK signaling .

How can the Phospho-BLK (Y501) Antibody be used to investigate BLK's role in oncogenic transformation?

The Phospho-BLK (Y501) Antibody can be leveraged to investigate BLK's oncogenic properties through several sophisticated approaches:

• Transformation studies: Research has demonstrated that the constitutively active form of BLK (Y501F) can transform growth factor-dependent Ba/F3 cells into factor-independent cells. The antibody can be used to confirm the absence of Y501 phosphorylation in Y501F mutant cells while monitoring phosphorylation at the activating tyrosine (Y388) using complementary tools .

• Cell survival analysis: BLK(Y501F)-transfected Ba/F3 cells show no increase in apoptosis following IL-3 withdrawal, unlike non-transfected or wild-type BLK-transfected cells. The antibody can help correlate phosphorylation status with apoptotic resistance .

• Inhibitor response studies: Src family kinase inhibitors like Lck inhibitor (LckI) and dasatinib selectively inhibit the proliferation of BLK(Y501F)-transformed cells. The antibody can monitor changes in phosphorylation patterns following inhibitor treatment to establish mechanism of action .

• Clinical sample analysis: In cutaneous T-cell lymphoma (CTCL), BLK appears to function as an oncogene. The antibody can be used to assess phosphorylation patterns in primary samples and correlate with disease progression or treatment response .

• Combination therapy investigations: Dasatinib and NF-κB inhibitors show additive effects on malignant proliferation in vitro. The antibody can help elucidate mechanisms behind these synergistic effects by tracking phosphorylation changes .

What methodological considerations are important when studying the relationship between BLK phosphorylation and B-cell receptor signaling?

When investigating BLK phosphorylation in B-cell receptor (BCR) signaling contexts, researchers should consider these methodological approaches:

• Temporal analysis of phosphorylation dynamics:

  • Monitor Y501 phosphorylation status before and after BCR stimulation

  • Establish time courses to determine rapid changes in phosphorylation

  • Compare with other Src family kinases involved in BCR signaling

• Spatial distribution studies:

  • Use the antibody in immunofluorescence to track subcellular localization of phosphorylated BLK

  • Investigate colocalization with BCR components and signaling intermediates

  • Employ high-resolution microscopy to visualize signaling microclusters

• Pathway integration analysis:

  • Combine with antibodies against other phosphorylated proteins in the BCR pathway

  • Use phosphatase inhibitors to preserve transient phosphorylation events

  • Apply pharmacological inhibitors to dissect the hierarchy of signaling events

• Functional correlation studies:

  • Correlate Y501 phosphorylation status with downstream functional outcomes

  • Compare effects of wild-type BLK versus Y501F mutant on BCR signaling strength

  • Investigate feedback mechanisms regulating BLK phosphorylation status

• Single-cell approaches:

  • Apply the antibody in flow cytometry or mass cytometry to assess heterogeneity in B-cell populations

  • Correlate phosphorylation status with B-cell developmental stages or activation states

How can Phospho-BLK (Y501) Antibody be used in conjunction with kinase inhibitor studies?

The Phospho-BLK (Y501) Antibody serves as a valuable tool in kinase inhibitor research:

• Inhibitor screening and validation:

  • Monitor Y501 phosphorylation status as a readout for inhibitor efficacy

  • Compare effects of specific BLK inhibitors versus broader Src family kinase inhibitors

  • Establish dose-response relationships between inhibitor concentration and phosphorylation status

• Mechanistic studies:

  • Dasatinib has been shown to inhibit Y388 phosphorylation and proliferation of BLK(Y501F)-transfected Ba/F3 cells

  • The antibody can help determine whether inhibitors affect Y501 phosphorylation directly or indirectly

  • Combine with total BLK antibodies to assess potential changes in protein expression versus phosphorylation

• Resistance mechanism investigation:

  • Track changes in Y501 phosphorylation in cells developing resistance to kinase inhibitors

  • Identify compensatory phosphorylation events in resistant cells

  • Monitor alterations in Y501 phosphorylation following combination treatments

• In vivo pharmacodynamics:

  • Use the antibody to assess inhibitor penetration and target engagement in animal models

  • Establish the relationship between inhibitor dosing, Y501 phosphorylation, and functional outcomes

  • Develop biomarker strategies for clinical translation

• Therapeutic window assessment:

  • Compare inhibitor effects on malignant versus normal cells

  • Determine threshold levels of inhibition required for anti-tumor effects

  • Correlate phosphorylation status with biomarkers of clinical response

What strategies can improve detection sensitivity when using Phospho-BLK (Y501) Antibody in samples with low expression?

For samples with low BLK expression or minimal phosphorylation at Y501, consider these sensitivity-enhancing approaches:

• Signal amplification methods:

  • For IHC/IF: Employ tyramide signal amplification or polymer-based detection systems

  • For western blotting: Use enhanced chemiluminescence substrates with extended exposure times

  • For ELISA: Consider biotin-streptavidin amplification systems with recommended dilution of 1:20000

• Sample enrichment techniques:

  • Perform immunoprecipitation of total BLK followed by phospho-detection

  • Use phospho-protein enrichment columns prior to analysis

  • Concentrate protein samples when possible while maintaining phosphorylation status

• Optimized blocking and antibody incubation:

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use optimized blocking buffers to reduce background while preserving specific signal

  • Consider carriers like BSA (0.5%) to stabilize antibody during incubation

• Phosphatase inhibitor optimization:

  • Include comprehensive phosphatase inhibitor cocktails in all buffers

  • Process samples rapidly at cold temperatures to minimize phosphatase activity

  • Consider specialized fixation protocols that better preserve phospho-epitopes

• Technical parameter optimization:

  • For IF/IHC: Test different antigen retrieval methods and fixation protocols

  • For western blotting: Optimize transfer conditions for higher molecular weight proteins

  • For all applications: Perform careful titration experiments to determine optimal antibody concentration

How can I quantify changes in BLK Y501 phosphorylation across experimental conditions?

Quantitative analysis of Y501 phosphorylation requires rigorous methodological approaches:

• Western blot quantification:

  • Use digital imaging systems with linear detection range

  • Include a standardized loading control or total BLK normalization

  • Apply appropriate statistical methods for replicate analysis

  • Consider phosphorylation ratio (phospho-BLK/total BLK) as a normalized measure

• ELISA-based quantification:

  • Develop a sandwich ELISA using capture antibody against total BLK and detection with Phospho-BLK (Y501)

  • Generate standard curves with recombinant phosphorylated protein

  • Follow recommended 1:20000 dilution for optimal performance

• Immunofluorescence quantification:

  • Use consistent exposure settings and acquisition parameters

  • Apply automated image analysis algorithms for unbiased quantification

  • Consider single-cell analysis rather than field-based measurements

  • Normalize phospho-signal to total BLK or appropriate cellular markers

• Flow cytometry:

  • Develop intracellular staining protocols optimized for phospho-epitopes

  • Use median fluorescence intensity as a quantitative measure

  • Include appropriate controls for autofluorescence and non-specific binding

  • Consider dual staining with total BLK for ratio-based measurements

• Comparative experimental design:

  • Include both positive controls (maximal phosphorylation) and negative controls (phosphatase-treated)

  • Design time-course experiments to capture dynamic phosphorylation changes

  • Employ multiple technical and biological replicates for statistical validity

How can Phospho-BLK (Y501) Antibody be utilized to study the dual role of BLK in B-cell malignancies and pancreatic beta-cell function?

The dual roles of BLK in different tissue contexts can be investigated using these specialized approaches:

• Tissue-specific phosphorylation pattern analysis:

  • Compare Y501 phosphorylation patterns between B-cells and pancreatic β-cells

  • Correlate phosphorylation status with tissue-specific function

  • Investigate tissue-specific regulatory mechanisms controlling Y501 phosphorylation

• Stimulus-response studies:

  • In B-cells: Monitor Y501 phosphorylation following B-cell receptor activation

  • In β-cells: Track phosphorylation changes in response to glucose stimulation

  • Compare kinetics and magnitude of phosphorylation responses between tissues

• Pathway integration analysis:

  • Map BLK signaling networks in each tissue context

  • Identify tissue-specific upstream regulators and downstream effectors

  • Investigate cross-talk with other signaling pathways relevant to each tissue

• Disease model applications:

  • B-cell malignancies: Study Y501 phosphorylation in lymphoma models and patient samples

  • Diabetes models: Investigate BLK phosphorylation in models of β-cell dysfunction

  • Compare phosphorylation patterns between normal and pathological states in each tissue

• Therapeutic targeting evaluation:

  • Assess tissue-specific responses to BLK inhibitors

  • Investigate potential therapeutic windows for targeting BLK in malignancies

  • Evaluate off-target effects on pancreatic function when targeting BLK in B-cell disorders

What are the emerging approaches for using Phospho-BLK (Y501) Antibody in precision medicine applications?

Emerging precision medicine applications for Phospho-BLK (Y501) Antibody include:

• Biomarker development:

  • Assess Y501 phosphorylation status in patient samples as a potential predictive biomarker

  • Correlate phosphorylation patterns with response to targeted therapies

  • Develop standardized assays suitable for clinical implementation

• Patient stratification strategies:

  • Classify patients based on BLK phosphorylation status

  • Identify subgroups likely to benefit from BLK-targeted therapies

  • Integrate with other molecular markers for comprehensive patient profiling

• Therapeutic monitoring:

  • Use the antibody to track changes in BLK phosphorylation during treatment

  • Develop minimally invasive methods to monitor phosphorylation in clinical settings

  • Establish thresholds of inhibition associated with clinical response

• Resistance mechanism identification:

  • Study alterations in Y501 phosphorylation in treatment-resistant disease

  • Investigate compensatory signaling pathways activated in resistant cases

  • Guide rational combination therapy approaches based on phosphorylation profiles

• Combination therapy design:

  • Research shows that dasatinib and NF-κB inhibitors have additive effects on malignant proliferation

  • Use the antibody to monitor pathway activities in response to combination treatments

  • Identify synergistic drug combinations based on complementary effects on BLK signaling